Table 1 Demographics, analytical data, and disease-related characteristics of patients with rheumatoid arthritis and control subjects
Control subjects (n = 210) | Patients with RA (n = 151) | p Value | |
|---|---|---|---|
Age, years | 58 ± 9 | 53 ± 11 | 0.000 |
Female sex, n (%) | 148 (70) | 120 (79) | 0.052 |
Body mass index, kg/m2 | 28 ± 5 | 28 ± 5 | 0.78 |
Waist circumference, cm | 92 ± 14 | 96 ± 13 | 0.015 |
Cardiovascular risk factors, n (%) | |||
Smoking | 42 (20) | 26 (17) | 0.51 |
Hypertension | 58 (27) | 45 (30) | 0.65 |
Dyslipidemia | 33 (15) | 54 (36) | 0.000 |
Diabetes | 0 (0) | 0 (0) | – |
Medication | |||
Statins | 14 (6) | 43 (28) | 0.000 |
Antihypertensive treatment | 35 (16) | 45 (30) | 0.003 |
Analytical data | |||
CRP, mg/dl | 1.0 (1.0–3.0) | 3.2 (1.5–5.8) | 0.000 |
ESR, mm/h | 10 ± 8 | 34 ± 22 | 0.000 |
Triglycerides, mg/dl | 104 ± 50 | 144 ± 92 | 0.000 |
HDL cholesterol, mg/dl | 63 ± 18 | 56 ± 15 | 0.000 |
LDL cholesterol, mg/dl | 135 ± 34 | 121 ± 31 | 0.000 |
Total cholesterol, mg/dl | 219 ± 37 | 206 ± 36 | 0.001 |
Lipoprotein A, mg/dl | 16 (9–39) | 35 (11–121) | 0.000 |
Apolipoprotein A1, mg/dl | 191 ± 35 | 170 ± 28 | 0.000 |
Apolipoprotein B, mg/dl | 102 ± 24 | 110 ± 63 | 0.11 |
ApoB/ApoA ratio | 0.55 ± 0.16 | 0.66 ± 0.30 | 0.000 |
Atherogenic index | 3.7 ± 4.0 | 4.0 ± 3.6 | 0.10 |
Disease-related data | |||
Disease duration, years | 6.6 (3.3–13.9) | ||
ACPA, n (%) | 89 (59) | ||
Rheumatoid factor, n (%) | 109 (72) | ||
Erosions, n (%) | 55 (36) | ||
Extra-articular manifestations, n (%) | 16 (11) | ||
DAS28-ESR | 3.7 ± 1.2 | ||
DAS28-CRP | 2.9 ± 1.0 | ||
SDAI | 15 (8–21) | ||
CDAI | 9 (5–16) | ||
HAQ | 0.630 (0.380–1.130) | ||
Current prednisone, n (%) | 57 (38) | ||
Prednisone current doses, mg/day | 5 (5–6) | ||
NSAIDs, n (%) | 69 (46) | ||
DMARDs, n (%) | 129 (85) | ||
Methotrexate, n (%) | 113 (75) | ||
Biologic drugs, n (%) | 35 (23) | ||
Anti-TNF-α drugs, n (%) | 20 (13) | ||